NCT06617858View on ClinicalTrials.gov

Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment

PHASE2RecruitingINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

December 4, 2024

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2028

Conditions

Colorectal Cancer

Interventions

DRUG

AMB-05X

Given by IV

Trial Locations (1)

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER